Trial reportClinical lymphoma, myeloma & leukemia2016
Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.
Trial report in Clinical lymphoma, myeloma & leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00980018 (An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Exploratory Trial to Assess the Improvement of Chronic Low-grade Non-hematologic Adverse Events Experienced by Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Treated With Imatinib When Switched to Nilotinib Treatment
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.Cancer medicine · 2018Trial
- Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.Annals of hematology · 2018Trial
- Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.International journal of clinical oncology · 2017Trial
- Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.European journal of haematology · 2026Article
- Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review.Current hematologic malignancy reports · 2025Article
- Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1Leukemia · 2025Article
- Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.Journal of the National Cancer Institute · 2022Article
- Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.Current hematologic malignancy reports · 2021Review
- The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review.Oncology reviews · 2021Article
- Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.Current hematologic malignancy reports · 2019Review
- [Patient-reported outcome and its application in hematological neoplasm].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019Article
- Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety.Frontiers in oncology · 2019Review
- Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia.Journal of cancer research and clinical oncology · 2017Article
- Understanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative StudyAsian Pacific journal of cancer prevention : APJCP · 2017Article
- Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.Journal of cancer research and clinical oncology · 2017Article
- Chronic myeloid leukemia: sequencing of TKI therapies.Hematology. American Society of Hematology. Education Program · 2016Review
- The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.Hematology. American Society of Hematology. Education Program · 2016Review
- Experience using Imatinib and then Nilotinib, as second line, in patient with chronic myeloid leukemia and previous bariatric surgery. A case report.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
Abstract
backgroundMany patients with chronic myeloid leukemia in chronic phase experience chronic treatment-related adverse events (AEs) during imatinib therapy. These AEs can impair quality of life and lead to reduced treatment adherence, which is associated with poor clinical outcomes. PATIENTS AND
methodsIn the phase II ENRICH (Exploring Nilotinib to Reduce Imatinib Related Chronic Adverse Events) study (N = 52), the effect of switching patients with imatinib-related chronic low-grade nonhematologic AEs from imatinib to nilotinib was evaluated.
resultsThree months after switching to nilotinib, 84.6% of the patients had overall improvement in imatinib-related AEs (primary endpoint). Of 210 imatinib-related AEs identified at baseline, 62.9% had resolved within 3 months of switching to nilotinib. Of evaluable patients, most had improvements in overall quality of life after switching to nilotinib. At screening, 65.4% of evaluable patients had a major molecular response (BCR-ABL1 ≤ 0.1% on the International Scale). After switching to nilotinib, the rate of the major molecular response was 76.1% at 3 months and 87.8% at 12 months. Treatment-emergent AEs reported with nilotinib were typically grade 1 or 2; however, some patients developed more serious AEs, and 8 patients discontinued nilotinib because of new or worsening AEs.
conclusionOverall, results from the ENRICH study demonstrated that switching to nilotinib can mitigate imatinib-related chronic low-grade nonhematologic AEs in patients with chronic myeloid leukemia in chronic phase, in conjunction with acceptable safety and achievement of molecular responses. This trial was registered at www.clinicaltrials.gov as NCT00980018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.